Sequential Chemoradiotherapy Compared to Radiotherapy in Endometrial Carcinoma

Elemam, Omima; Abdelkhalek, Seham; Abdelmoety, Doaa; Aboelnaga, Engy; Baraka, Reem; Zeeneldine, Ahmed

doi:10.31557/APJCP.2020.21.5.1327

Sequential Chemoradiotherapy Compared to Radiotherapy in Endometrial Carcinoma

Document Type : Research Articles

Authors

¹ Oncology Center, King Abdullah Medical City, Makkah, Saudi Arabia.

² Oncology Center, Mansoura University, Mansoura, Egypt.

³ Department of Radiotherapy , Mansoura University, Mansoura, Egypt.

⁴ Research Center, King Abdullah Medical City, Makkah, Saudi Arabia.

⁵ Department of Biology, Colorado State University, Fort Collins, USA.

⁶ NCI, Faculty of Medicine, Cairo University, Cairo, Egypt.

10.31557/APJCP.2020.21.5.1327

Abstract

Background: The role of combined modality in the adjuvant treatment of Endometrial Cancer has not been established. This study aims to assess the benefits of Sequential Chemoradiotherapy (SCRT) compared to Radiotherapy (RT) alone in the treatment of patients with Endometrial Cancer. Methods: Retrospective analysis of patients with Endometrial Cancer stage I to stage III C at King Abdullah Medical city, Makkah. Each group of patients was assigned to receive External pelvic RT, brachytherapy or both. While a second group received SCRT consisting of six cycles of Carboplatin (AUC 5) and Paclitaxel 175 mg/m2 followed by radiotherapy. Results: Fifty-six women were treated of which 26 received SCRT and 30 received RT. The two groups had a median age of 58 years old ranging from 34 – 84 years old with no other statistically significant difference. Patients who received SCRT had poorer prognostic tumor characteris-tics. Median follow-up was 29.6 months (95% CI: 19.6-39.5 months). All deaths (n=5) were exclusively in the RT group. The 2 and 4-year OS rates were 100% and 100% in SCRT group versus 87.3% and 64.9% in RT group (hazard ratio [HR] 0.018 [95% CI: 0-24.4; p= 0.038); The 2- and 4-year DFS were 100% and 100% in SCRT group versus 78.1% and 43.9% in RT group (HR 0.102 [95% CI: 0.103-0.805; p= 0.008). Conclusion: Adjuvant chemotherapy given before radiotherapy for Endometrial Cancer may lessen the effect of high-risk features on the DFS and OS. Randomized clinical trials are needed to determine the benefits of early Systemic Therapy.

Keywords

Main Subjects